share_log

天士力(600535):研发管线高效推进 业绩增速符合预期

Tianshili (600535): The R&D pipeline efficiently promotes performance growth in line with expectations

西部證券 ·  Apr 29

Incident: Tianshili released its 2023 annual report. During the reporting period, it achieved revenue of 8.674 billion yuan (+0.42% YoY), net profit of 1,071 million yuan (YoY +505.34%), net profit of 1,181 million yuan (YoY +60.11%); 2024Q1 achieved operating income of 2,049 million yuan (-1.73% YoY) and net profit of 295 million yuan (YoY +5.22%), which is in line with expectations.

Steady growth in performance. By industry, the pharmaceutical business achieved 1,215 billion yuan (-14.21% YoY); the pharmaceutical industry achieved 7.421 billion yuan (+3.22% YoY), and its central cerebrovascular, anti-tumor/cold fever/liver disease treatment/others achieved revenue of 52.54/1.90/5.08/6.57/812 million yuan respectively, +3.45%/-39.67%/+18.42%/+12.96%/+3.38%; gross margin was 74.93%/65.34%/61.81%/61.81%/ 82.18%/61.47%, +2.18pct/ +0.17pct/+10.17pct/-0.65pct/-3.4pct. Revenue from anti-tumor products decreased by 39.67% compared to the same period last year, mainly due to Diqing's implementation of centralized volume procurement prices for inter-provincial alliances in July 2022. Collection prices have been implemented for more than 1 year, and the impact of price cuts on the company's performance has weakened. 2024Q1 anti-tumor products achieved revenue of 55 million yuan (+31.74% year over year), mainly due to the increase in sales volume of Tiqing.

The R&D pipeline is progressing efficiently, and many products have entered clinical phase III. In 2023, the company invested 1,315 billion yuan (+29.49% year over year). Through the “four-in-one” R&D model, the company has a R&D pipeline covering 98 products under development, including 41 Class 1 innovative drugs, 36 in clinical trials, and 26 in clinical phase II and phase III: 2 classic traditional Chinese medicines, loquat lung cleansing drink and Wen Jingtang, submitted production applications; 9 innovative traditional Chinese medicines are in phase III clinical research.

Give it an “gain” rating. The estimated net profit for 2024-2026 is 11.74/12.92/1,430 billion yuan, up 9.6%/10.0%/10.7% year-on-year, EPS is 0.79/0.86/0.96 yuan, and the corresponding PE is 19.5/17.8/16.1x, respectively. Considering that the company has strong R&D strength, brand power and mature marketing system, it was given an “increase in weight” rating.

Risk warning: R&D innovation risk, policy adjustment risk, cost fluctuation risk

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment